Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
OwnerCindy Baulch-Brown, Andrew Spencerinventors
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for treatment of malignancies, in particular multiple myeloma (MM), comprises in combination a bisphosphonate, e.g. zoledronic acid or a salt or ester, and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.
Claims16
A pharmaceutical composition for treatment of malignancies which comprises in combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use.
Use of an HMG-CoA reductase inhibitor for the preparation of a medicament, for use in combination with a bisphosphonate for treatment of a malignant disease.
Use of a bisphosphonate for the preparation of a medicament for use in combination with an HMG-CoA reductase inhibitor for treatment of a malignant disease.
Use of an HMG-CoA reductase inhibitor in combination with a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.
A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.
A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of an HMG-CoA reductase inhibitor.
Dependencies are inferred from the claim text.